Glaukos Corporation is committed to transforming glaucoma therapy.
To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management.
Today, we are at the beginning with an innovative micro technology. In collaboration with our clinician partners, we are building technology towards a safer and more effective treatment for preserving vision in patients with primary open-angle glaucoma.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 07/01/01 | Series B | 3M | Unknown |
People
Thomas Burns (President/CEO)
Competitors
BiCOM Inc.:
BiCOM Inc reveals Unique medical devices through out the globe. BiCOM has introduced a glaucoma measuring… See Company Profile »
News
Life sciences briefing: Thursday, Jan. 3, 2008
January 4, 2008 2:49 am
TODAY’S HEADLINES: Gelesis draws in $16M for obesity treatments (release) Tempo Pharma raises $8B for nanoparticle drugs (release) Calistoga Pharma… Continue reading ⟩
Forsight Labs launches glaucoma treatment co., Transcend, with $7M
November 10, 2006 1:51 pm
Medical incubator ForSight Labs has launched glaucoma treatment company, Transcend Medical, with a $7 million in a first round of… Continue reading ⟩